RCKT · Healthcare

Rocket Pharmaceuticals Inc

USA Healthcare Filing: 2026-06-30

29/100

Smart-money confidence1 of 3 sources positive

Below average interest

No standout activity across the feeds we track.

What this band has actually done: stocks scoring 25–45 beat the S&P 500 over the next three months 45.3% of the time, across 39,662 cases since 2015. That is below a coin flip — and so is every other band, because the median stock loses to a cap-weighted index. How we measured this

Hedge funds

Congress

No data

Insiders

No data

Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. · how the score works

Market cap

$284M

Industry

Biotechnology

Sector

Healthcare

Exchange

NasdaqGM

About ROCKET PHARMACEUTICALS INC

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive…

Who's behind the signal

Every informed buyer we can see on RCKT, across all three feeds.

Hedge funds · 8

Citadel Advisors New position

Maverick Capital (Ainslie) Increased +10%

Millennium Management (Englander) Increased +28%

AQR Capital Management Increased +10%

Renaissance Technologies Increased +24%

Tudor Investment (Paul Tudor Jones) Unchanged

+2 more in the full breakdown below ↓

Congress · 0

No congressional trades on record.

Insiders

No significant Form 4 insider activity in the window.

Not a model pick — but on our radar. ROCKET PHARMACEUTICALS INC isn't in the top-10 model right now, but 8 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.

Investors

New positions

Increasing

Decreasing

Unchanged

Price History

Loading price data...

Return: High: Low:

Who's Holding This Stock

Position sizes and recent activity from tracked institutional investors

Citadel Advisors

Trust weight: 1.0×

New position

% of portfolio

0.0%

Position change

NEW

0.0% of Citadel Advisors's portfolio

Maverick Capital (Ainslie)

Trust weight: 1.2×

Increased +10%

% of portfolio

0.1%

Position change

+10%

0.1% of Maverick Capital's portfolio

Millennium Management (Englander)

Trust weight: 1.0×

Increased +28%

% of portfolio

0.0%

Position change

+28%

0.0% of Millennium Management's portfolio

AQR Capital Management

Trust weight: 1.0×

Increased +10%

% of portfolio

0.0%

Position change

+10%

0.0% of AQR Capital Management's portfolio

Renaissance Technologies

Trust weight: 1.0×

Increased +24%

% of portfolio

0.0%

Position change

+24%

0.0% of Renaissance Technologies's portfolio

Tudor Investment (Paul Tudor Jones)

Trust weight: 1.2×

Unchanged

% of portfolio

0.0%

Position change

—

0.0% of Tudor Investment's portfolio

Point72 (Steve Cohen)

Trust weight: 1.1×

Decreased −34%

% of portfolio

0.0%

Position change

−34%

0.0% of Point72's portfolio

D.E. Shaw & Co

Trust weight: 1.0×

Decreased −56%

% of portfolio

0.0%

Position change

−56%

0.0% of D.E. Shaw & Co's portfolio

Portfolio Allocation

How much of each investor's portfolio is allocated to ROCKET PHARMACEUTICALS INC

⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell ROCKET PHARMACEUTICALS INC or any security.

Get the Weekly Update

Every week, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.

Also alert me when a politician or insider makes a major trade ($500K+)

Free forever · No spam · Unsubscribe anytime